Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

Transplantation

Volumn 80, Issue 8, 2005, Pages 1051-1059

  Kirk, Allan D ^a,d   Mannon, Roslyn B ^a   Kleiner, David E ^b   Swanson, John S ^c   Kampen, Robert L ^a   Cendales, Linda K ^a   Elster, Eric A ^a   Wakefield, Terri ^a   Chamberlain, Christine ^a   Hoffmann, Steven C ^a   Hale, Douglas A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Alemtuzumab; Deoxyspergualin; Immunosuppression; Rejection; Tolerance; Transplantation

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; CHEMOKINE; CLOTRIMAZOLE; COTRIMOXAZOLE; METHYLPREDNISOLONE; RAPAMYCIN; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T CELL DEPLETION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CHEMOKINES; CREATINE; FEMALE; GRAFT REJECTION; GUANIDINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPH NODES; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSPLANTATION TOLERANCE;

EID: 27744481221     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000174341.49741.8f     Document Type: Article

References (20)

1. Chen Z, Cobbold S, Metcalfe S, Waldmann H. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur J Immunol 1992; 22: 805.
2. Shizuru JA, Seydel KB, Flavin TF, et al. Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. Transplantation 1990; 50: 366.
3. Strober S, Modry DL, Hoppe RT, et al. Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. J Immunol 1984; 132: 1013.
4. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
5. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
6. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
7. Knechtle SJ, Pirsch JD, H, Fechner J Jr., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
8. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662.
9. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505.
10. Axelrod D, Leventhal JR, Gallon LG, et al. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplant recipients. Am J Transplant 2005; 5: 1423.
11. Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005; 79: 1184.
12. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Campath-1H. Transplantation 2003; 76: 120.
13. Thomas JM, Contreras JL, Jiang XL. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999; 68: 1660.
14. Thomas JM, Hubbard WJ, Sooudi SK, Thomas FT. STEALTH matters: a novel paradigm of durable primate allograft tolerance. Immunol Rev 2001; 183: 223.
15. Amemiya H. Deoxyspergualin: immunosuppressive properties. Norwalk, CT: Appleton and Lange, 1989.
16. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
17. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
18. Hoffmann SC, Kampen RL, Amur S, et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia/reperfusion injury. Transplantation 2002; 74: 916.
19. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573.
20. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986.